SuperworthOmada Health OMDA
- Market cap
- $1.2B
- PE
- 316×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $309.8M
- +48% on a year ago
- Net margin
- 1.4%
- Free cash flow yield
- 2.0%
Omada Health trades at 316× trailing earnings. Revenue was $309.8M over the last twelve months, up 48% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $35.1M | $41.2M | $45.5M | $48M | $55M+57% | $61.4M+49% | $68M+50% | $75.8M+58% | $78M+42% | $87.8M+43% | |
| Cost of revenue | $17.7M | $16.4M | $17M | $15.8M | $23.1M+30% | $21.1M+29% | $23M+35% | $22.2M+40% | $29.4M+27% | $24M+14% |
| Gross profit | $17.3M | $24.8M | $28.6M | $32.1M | $31.9M+84% | $40.3M+62% | $45.1M+58% | $53.7M+67% | $48.7M+53% | $63.8M+58% |
| R&D | $8.9M | $9M | $8.8M | $9.2M | $8.8M−1% | $10M+12% | $10.3M+16% | $11.6M+26% | $12.7M+44% | $14.6M+46% |
| SG&A | $26.4M | $25.9M | $28.2M | $30M | $31.5M+19% | $34.6M+34% | $37.3M+32% | $38.8M+29% | $40.8M+30% | $45.6M+32% |
| −$18M | −$10M | −$8.5M | −$7.1M | −$8.4M−53% | −$4.3M−57% | −$2.5M−71% | $3.3M | −$4.8M−43% | $3.5M | |
| Interest expense | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M−5% | $1.1M−3% | $353K−69% | $13K−99% | $18K−98% | $14K−99% |
| Pre-tax income | −$19M | −$10.7M | −$9.2M | −$8.3M | −$9.4M−50% | −$5.3M−50% | −$3.2M−66% | $5.2M | −$3M−69% | $5.3M |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$19M | −$10.7M | −$9.2M | −$8.3M | −$9.4M−50% | −$5.3M−50% | −$3.2M−66% | $5.2M | −$3M−69% | $5.3M |
| −$2.53 | −$1.40 | −$1.18 | −$1.04 | −$1.15−55% | −$0.24−83% | −$0.06−95% | $0.09 | −$0.05−96% | $0.08 | |
| 7.5M | 7.6M | 7.8M | 8M | 8.2M+10% | 22M+187% | 57.7M+640% | 58.1M+630% | 58.9M+615% | 63.9M+191% |
Revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
R&D: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Operating income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Income tax: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Net income: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
EPS, diluted: 3 periods, Q1 FY24 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY24: share-days: the 6-month average less the second quarter's. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Omada Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| SBCSBC Medical | $543M | 11.2× | 8.2× | 3.1× | −7% | 28.0% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| AVAHAveanna Healthcare | $2.9B | 10.9× | 21.8× | 1.1× | +20% | 10.6% | |
| Peer median | $2B | 21.8× | 29.2× | 1.3× | +8% | 6.3% |
More on Omada Health
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .